Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
US Army
Colorcon
McKesson
Cerilliant
Merck
Dow
Accenture
Farmers Insurance

Generated: February 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DAPAGLIFLOZIN

« Back to Dashboard

Clinical Trials for Dapagliflozin

Trial ID Title Status Sponsor Phase Summary
NCT00162305 A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects Completed Bristol-Myers Squibb Phase 2 The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
NCT00162305 A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects Completed AstraZeneca Phase 2 The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
NCT00263276 A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus Completed Bristol-Myers Squibb Phase 2 The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied
NCT00263276 A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus Completed AstraZeneca Phase 2 The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied
NCT00357370 A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes Completed AstraZeneca Phase 2/Phase 3 The purpose of this clinical research study is to learn if BMS-512148, added to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone), can help reduce the blood sugar levels compared to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone) alone, in subjects with type 2 diabetes. The safety of this treatment will also be studied.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Dapagliflozin

Condition Name

Condition Name for Dapagliflozin
Intervention Trials
Type 2 Diabetes Mellitus 42
Type 2 Diabetes 35
Diabetes Mellitus, Type 2 31
Obesity 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dapagliflozin
Intervention Trials
Diabetes Mellitus 131
Diabetes Mellitus, Type 2 124
Diabetes Mellitus, Type 1 13
Insulin Resistance 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dapagliflozin

Trials by Country

Trials by Country for Dapagliflozin
Location Trials
United States 805
Canada 155
Mexico 93
India 52
Japan 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dapagliflozin
Location Trials
Texas 55
California 41
Florida 40
New York 31
Ohio 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dapagliflozin

Clinical Trial Phase

Clinical Trial Phase for Dapagliflozin
Clinical Trial Phase Trials
Phase 4 70
Phase 3 55
Phase 2/Phase 3 3
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dapagliflozin
Clinical Trial Phase Trials
Completed 73
Recruiting 62
Not yet recruiting 40
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dapagliflozin

Sponsor Name

Sponsor Name for Dapagliflozin
Sponsor Trials
AstraZeneca 126
Bristol-Myers Squibb 44
The University of Texas Health Science Center at San Antonio 9
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dapagliflozin
Sponsor Trials
Industry 186
Other 142
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Accenture
Moodys
Federal Trade Commission
McKinsey
Chinese Patent Office
Medtronic
Teva
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.